US biotechnology company invests at Klaipėda FEZ FlexStart facility

American capital biotechnology company Cureline Inc. is investing EUR 3.5 million in the construction of a new biotechnology plant and research laboratory in Klaipėda FEZ. The plant, laboratory and administrative premises will be located in the FlexStart facility. The start of operations is planned for the first half of 2024.

The new plant and laboratory will be managed by Memel Biotech, a subsidiary of Cureline Inc. group, VZ.LT reports.

Its CEO Agnė Vaitkevičienė says that the company will be involved in the production of medical products, including advanced therapy drugs for clinical trials, with direct customers being pharmaceutical companies and medical institutions worldwide.

“We will be the first in Lithuania to be able to develop this level of products for clinical trials. We will also be one of the few in the Baltic States and Poland. This market is not yet widely occupied in the region, but the global demand for such products is huge, so not only we as a company, but also Lithuania as a country has the potential to become a centre of advanced therapeutic technologies,” the company’s announcement quotes A. Vaitkevičienė, CEO of Memel Biotech, as saying.

According to her, Memel Biotech will be equipped with special premises complying with the standards for the production of sterile medical products, where innovative biotechnological products for personalised medicine will be developed and manufactured.

The estimated floor area of the plant with commercial premises is 850 sqm. The company intends to recruit up to 25 highly qualified professionals over the next two years. Until now, Cureline Baltic has had an administrative office and an animal laboratory in Vilnius.